248 Exploring Early Practice and Application of NovoSorbⓇ Biodegradable Temporising Matrix in the United Kingdom: A Case Series on Wound Reconstruction

Abstract Aim To identify patients treated with NovoSorbⓇ Biodegradable Temporising Matrix (BTM). To examine defect aetiology, indications of BTM and operation details. To investigate treatment outcomes and possible complications. Method From October 2021 to February 2023, 12 patients were treated with BTM for wound reconstruction at Lister Hospital, Stevenage. Patient information, defect size, the reason for BTM use, operation details, and complications were recorded from medical records. The length of initial hospital stays, the time from BTM application to integration, and the length of inpatient stay for post-secondary reconstruction were noted. Indications for BTM were grouped into four categories: covering wounds with exposed bone, covering wounds with exposed tendon, burn wound temporisation and aesthetic reconstruction. Complications were grouped into infection and non-adherence. Results This case series comprises defects from head to ankle caused by burns, surgical wounds, post-oncological resection, dermal infections, or traumatic loss. The median time for inpatient stay was 3.5 days, and patients who required skin grafts after full BTM integration were treated as day cases. One case had the post-operative complication of infection. Conclusions The team found that the BTM is a versatile dermal substitute that can be used to treat various defects in different parts of the body. Most patients showed no signs of infection or excessive scarring supporting the use of BTM. However, some cases were complicated, possibly due to other medical conditions. Therefore, careful patient selection, close monitoring, and appropriate wound care are recommended.